Tectonic Positive Topline Data from Phase 1b Part B in Pulmonary Hypertension

 

• TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)
• TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactions
• Results support potential expansion of TX45’s addressable Group 2 PH patient population to PH‑HFrEF
• Company to host webcast today, October 29th at 4:30 p.m. ET

Tectonic will host a webcast today, October 29, 2025, at 4:30 p.m. ET. The live webcast of the event will be available here and under Events and Presentations in the Investors section of the Company’s website at www.tectonictx.com. A replay of the webcast will also be available on the Company’s website after the call’s conclusion.

https://www.globenewswire.com/news-release/2025/10/29/3176829/0/en/Tectonic-Therapeutic-Announces-Positive-Topline-Data-from-Phase-1b-Part-B-Clinical-Trial-for-TX45-in-Patients-with-Group-2-Pulmonary-Hypertension-in-HFrEF.html